circCDYL Acts as a Tumor Suppressor in Triple Negative Breast Cancer by Sponging miR-190a-3p and Upregulating TP53INP1

Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death among females. Circular RNAs (circRNAs) have been implicated in the initiation and development of cancer. Here, we explored the biological role and regulatory mechanism of circCDYL in breast cancer. The expression and correlation of circCDYL/miR-190a-3p/TP53INP1 axis in breast cancer tissues and cells were determined by quantitative polymerase chain reaction and Western blot. Cell-counting Kit-8, colony formation, cell migration, and invasion assays were applied to investigate the biological roles of circCDYL in breast cancer development and progression. CircCDYL were down-regulated in breast cancer tissues and cells, the expression of which positively correlated with patients’ survival rate. CircCDYL worked as a “sponge,” binding to miR-190a-3p directly, which inhibited the expression of miR-190a-3p and relieved the inhibition of tumor suppressor gene TP53INP1. CircCDYL promotes apoptosis and inhibits proliferation of the malignant phenotype of breast cancer through regulating miR-190a-3p/TP53INP1 axis, which suggests that circCDYL is a potential therapeutic target for breast cancer. Circular RNAs (circRNAs) have been implicated in the initiation and development of cancer. In this study, we found that circCDYL promotes apoptosis and inhibits the proliferation of the malignant phenotype of breast cancer through the regulating miR-190a-3p/TP53INP1 axis. Our results suggests that circCDYL is a potential therapeutic target for breast cancer.